{
    "organizations": [],
    "uuid": "806838052967eeb52d3d83d5b67b1961128ecde0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aptevo-therapeutics-announces-ind/brief-aptevo-therapeutics-announces-ind-submission-for-apvo436-idUSFWN1S8086",
    "ord_in_thread": 0,
    "title": "BRIEF-Aptevo Therapeutics Announces IND Submission For APVO436",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1 (Reuters) - Aptevo Therapeutics Inc:\n* APTEVO THERAPEUTICS ANNOUNCES IND SUBMISSION FOR APVO436 * APTEVO THERAPEUTICS INC - ON TRACK TO COMMENCE PHASE 1 CLINICAL TRIAL OF APVO436 IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME IN Q4 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T21:11:00.000+03:00",
    "crawled": "2018-05-02T16:19:10.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aptevo",
        "therapeutic",
        "inc",
        "aptevo",
        "therapeutic",
        "announces",
        "ind",
        "submission",
        "apvo436",
        "aptevo",
        "therapeutic",
        "inc",
        "track",
        "commence",
        "phase",
        "clinical",
        "trial",
        "apvo436",
        "acute",
        "myeloid",
        "leukemia",
        "myelodysplastic",
        "syndrome",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}